-+ 0.00%
-+ 0.00%
-+ 0.00%

CARDIOL THERAPEUTICS ACHIEVES PHASE III MAVERIC ENROLLMENT TARGET AHEAD OF SCHEDULE AND EXPANDS PIVOTAL TRIAL TO STRENGTHEN ASSESSMENT OF CARDIOLRX™'S EFFICACY

路透·09/23/2026 10:00:01

請登錄查看新聞詳情